Vitamin D and multiple sclerosis: a comprehensive review

MB Sintzel, M Rametta, AT Reder - Neurology and therapy, 2018 - Springer
Numerous observational studies have suggested that there is a correlation between the
level of serum vitamin D and MS risk and disease activity. To explore this hypothesis, a …

Defining the clinical course of multiple sclerosis: the 2013 revisions

FD Lublin, SC Reingold, JA Cohen, GR Cutter… - Neurology, 2014 - neurology.org
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important
for communication, prognostication, design and recruitment of clinical trials, and treatment …

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis

X Montalban, R Gold, AJ Thompson… - Multiple Sclerosis …, 2018 - journals.sagepub.com
Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …

Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome

DT Okuda, O Kantarci, C Lebrun‐Frénay… - Annals of …, 2023 - Wiley Online Library
Objective The radiologically isolated syndrome (RIS) represents the earliest detectable pre‐
clinical phase of multiple sclerosis (MS). This study evaluated the impact of therapeutic …

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

H Wiendl, R Gold, T Berger, T Derfuss… - Therapeutic …, 2021 - journals.sagepub.com
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous
system characterized by inflammatory demyelination and axonal/neuronal damage. The …

[HTML][HTML] Brain health: time matters in multiple sclerosis

G Giovannoni, H Butzkueven, S Dhib-Jalbut… - Multiple sclerosis and …, 2016 - Elsevier
Introduction We present international consensus recommendations for improving diagnosis,
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …

Defining high, medium and low impact prognostic factors for develo** multiple sclerosis

M Tintore, À Rovira, J Río, S Otero-Romero… - Brain, 2015 - academic.oup.com
Natural history studies have identified factors that predict evolution to multiple sclerosis or
risk of disability accumulation over time. Although these studies are based on large …

Evolving concepts in the treatment of relapsing multiple sclerosis

G Comi, M Radaelli, PS Sørensen - The Lancet, 2017 - thelancet.com
In the past 20 years the treatment scenario of multiple sclerosis has radically changed. The
increasing availability of effective disease-modifying therapies has shifted the aim of …

[HTML][HTML] Multiple sclerosis: immunopathology and treatment update

N Dargahi, M Katsara, T Tselios, ME Androutsou… - Brain sciences, 2017 - mdpi.com
The treatment of multiple sclerosis (MS) has changed over the last 20 years. All
immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a …

Optic neuritis

AT Toosy, DF Mason, DH Miller - The Lancet Neurology, 2014 - thelancet.com
Acute optic neuritis is the most common optic neuropathy affecting young adults. Exciting
developments have occurred over the past decade in understanding of optic neuritis …